Alkem Laboratories Limited (ALKEM.BO)
INR 4880.35
(0.88%)
INR 4880.35
(0.88%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 14.18 Billion INR | 1.56% |
| 2022 | 13.96 Billion INR | -47.65% |
| 2021 | 26.68 Billion INR | 54.36% |
| 2020 | 17.28 Billion INR | 0.34% |
| 2019 | 17.22 Billion INR | 82.47% |
| 2018 | 9.44 Billion INR | -5.36% |
| 2017 | 9.97 Billion INR | 51.28% |
| 2016 | 6.59 Billion INR | 0.26% |
| 2015 | 6.57 Billion INR | -49.83% |
| 2014 | 13.11 Billion INR | 37.09% |
| 2013 | 9.56 Billion INR | -22.81% |
| 2012 | 12.38 Billion INR | 54.19% |
| 2011 | 8.03 Billion INR | 9.82% |
| 2010 | 7.31 Billion INR | 952.13% |
| 2009 | 695.46 Million INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 14.18 Billion INR | 1.56% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 14.42 Billion INR | 0.0% |
| 2023 Q4 | 14.18 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 FY | 13.96 Billion INR | -47.65% |
| 2022 Q4 | 13.96 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 19.27 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2021 Q2 | 17.31 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 26.68 Billion INR | 54.36% |
| 2021 Q4 | 26.68 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 17.28 Billion INR | 0.0% |
| 2020 Q2 | 14.18 Billion INR | 0.0% |
| 2020 FY | 17.28 Billion INR | 0.34% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 17.22 Billion INR | 0.0% |
| 2019 Q2 | 14.13 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 17.22 Billion INR | 82.47% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 9.44 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 FY | 9.44 Billion INR | -5.36% |
| 2018 Q2 | 10.12 Billion INR | 0.0% |
| 2017 Q4 | 9.97 Billion INR | 0.0% |
| 2017 FY | 9.97 Billion INR | 51.28% |
| 2017 Q1 | - INR | -100.0% |
| 2017 Q2 | 10.54 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 6.59 Billion INR | 0.26% |
| 2016 Q2 | 6.67 Billion INR | 0.0% |
| 2016 Q4 | 6.59 Billion INR | 0.0% |
| 2015 Q2 | 11.19 Billion INR | 0.0% |
| 2015 Q4 | 6.57 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 6.57 Billion INR | -49.83% |
| 2014 Q4 | 13.11 Billion INR | 0.0% |
| 2014 FY | 13.11 Billion INR | 37.09% |
| 2014 Q1 | - INR | 0.0% |
| 2013 FY | 9.56 Billion INR | -22.81% |
| 2012 FY | 12.38 Billion INR | 54.19% |
| 2011 FY | 8.03 Billion INR | 9.82% |
| 2010 FY | 7.31 Billion INR | 952.13% |
| 2009 FY | 695.46 Million INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | 56.672% |
| NATCO Pharma Limited | 3.71 Billion INR | -282.115% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -2082.29% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -1856.789% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 352.8 Million INR | -3920.437% |
| Alpa Laboratories Limited | 52.46 Million INR | -26935.357% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | -176.407% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -30747.071% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 78.663% |
| Bajaj HealthCare Limited | 3.32 Billion INR | -326.174% |
| Bliss GVS Pharma Limited | 998.4 Million INR | -1320.682% |
| Brooks Laboratories Limited | 56.41 Million INR | -25040.644% |
| Divi's Laboratories Limited | 30 Million INR | -47180.333% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | 29.15% |
| Eris Lifesciences Limited | 27.81 Billion INR | 49.001% |
| FDC Limited | 205.18 Million INR | -6812.835% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | -15.231% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -8171.577% |
| Granules India Limited | 13.15 Billion INR | -7.859% |
| Gufic Biosciences Limited | 3.32 Billion INR | -326.057% |
| Hester Biosciences Limited | 2.44 Billion INR | -480.416% |
| Indoco Remedies Limited | 6.71 Billion INR | -111.085% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -8433.535% |
| Ipca Laboratories Limited | 14.38 Billion INR | 1.387% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -15764.109% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -633.296% |
| Lasa Supergenerics Limited | 220.76 Million INR | -6325.064% |
| Laurus Labs Limited | 25.77 Billion INR | 44.967% |
| Lupin Limited | 29.21 Billion INR | 51.454% |
| Mankind Pharma Limited | 2.07 Billion INR | -584.652% |
| Medicamen Biotech Limited | 308.17 Million INR | -4502.657% |
| Medico Remedies Limited | 80.5 Million INR | -17519.125% |
| Megasoft Limited | 1.47 Billion INR | -864.596% |
| Piramal Pharma Limited | 47.1 Billion INR | 69.886% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Sigachi Industries Limited | 1.43 Billion INR | -891.537% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -2219.558% |
| Unichem Laboratories Limited | 2.47 Billion INR | -473.062% |
| Wanbury Limited | 1.16 Billion INR | -1117.68% |
| Windlas Biotech Limited | 36.41 Million INR | -38856.605% |
| ZIM Laboratories Limited | 1.08 Billion INR | -1203.393% |
| Zydus Lifesciences Limited | 8.04 Billion INR | -76.375% |
| Procter & Gamble Health Limited | 95.6 Million INR | -14736.925% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -81969.664% |
| Bal Pharma Limited | 1.39 Billion INR | -915.701% |
| Strides Pharma Science Limited | 25.16 Billion INR | 43.644% |
| Venus Remedies Limited | 413.3 Million INR | -3331.914% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | -397.252% |
| Nectar Lifesciences Limited | 6.35 Billion INR | -123.183% |
| Shilpa Medicare Limited | 9.37 Billion INR | -51.315% |
| Aarti Drugs Limited | 5.64 Billion INR | -151.371% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -4229.701% |
| Suven Life Sciences Limited | 7.09 Million INR | -199760.504% |
| Ind-Swift Limited | 10.13 Billion INR | -39.883% |
| Valiant Laboratories Limited | 767.08 Million INR | -1749.093% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | -275.579% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | -40.228% |
| Themis Medicare Limited | 957.92 Million INR | -1380.716% |
| Hikal Limited | 8.17 Billion INR | -73.489% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 64.734% |
| Sequent Scientific Limited | 4.87 Billion INR | -190.841% |
| Novartis India Limited | 69.7 Million INR | -20250.215% |
| Wockhardt Limited | 23.56 Billion INR | 39.796% |
| Jubilant Pharmova Limited | 36.64 Billion INR | 61.288% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -323073.844% |
| Neuland Laboratories Limited | 953.89 Million INR | -1386.965% |
| Morepen Laboratories Limited | 289.99 Million INR | -4791.204% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -4382.044% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | -1340.12% |